The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
SieversE.L., LarsonR.A., EsteyE.Efficacy and safety of CMA-676 in patients with AML in first relapse. Presented at the 41st Annual Meeting of the American Society of Hematology (ASH); 1999 December 3-7, New Orleans, LA. Abstract 3079.
2.
van der VeldenV.H.J., BernsteinI., VosB.In vivo targeting of the humanized CD33 antibody CMA-676 in AML patients: Rapid saturation and internalization by leukemic blasts and normal myeloid cells. Presented at the American Society of Hematology (ASH) 41st Annual Meeting; 1999 December 3-7;New Orleans, LA. Abstract 4273.
3.
SieversE.L., AppelbaumF.R., SpeilbergerR.T.Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: CCCA Phase I Study of an anti-CD33 calcheamicin immunoconjugate. Blood.1999; 93: 3678–84.
4.
MullerF.O., TerblancheJ., SchallR.Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol.1997; 44: 335–41.
5.
DeSyW.A., De MeyerJ.M., CasselmanR.A comparative study of a long acting luteinizing Hormone releasing hormone agonist (decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Acta Urologica Belgica.1986; 54(2): 221–9.
6.
KuhnJ.M., AbourachidH., BrucherP.A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol.1997; 32(4): 397–403.
7.
BouchotO., SoretJ.Y., JacqminD.Three-month sustained-release form of triptorelin in patient with advanced prostatic ade-nocarcinoma: Results of an open pharmacodynamic and pharmacokinetic multicenter study. Horm Res.1998; 50: 89–93.
8.
ParmarH., PhillipsR.H., RustinG.Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (Decapeptyl) microcapsules. Biomed Pharmacother.1988; 42: 531–8.
9.
Gonzalez-BarcenaD., Perez-SanchezP., Ureta-SanchezS.Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH. Prostate.1985; 7: 21–30.
10.
AppelbaumF.R.Antibody-targeted therapy for myeloid leukemia. Semin Hematol.1999; 36(suppl 1): 2–8.
11.
ApplebaumF.R.Novel therapies of acute myeloid leukemia based on biologic aspects of the disease. Cancer Res Ther Control.1998; 7(suppl 1-2):137–40.
12.
MatthewsD.C.Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia.1998; 12(suppl 1): S33–6.
13.
WeinerL.M.An overview of monoclonal antibody therapy of cancer. Semin Oncol.1999; 26(4): 41–50.
